ESSA Pharma Inc

詳細情報 ESSA Pharma Inc 企業名

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

企業情報

企業コードEPIX

会社名ESSA Pharma Inc

上場日Feb 22, 2021

最高経営責任者「CEO」Dr. David Ross Parkinson, M.D.

従業員数35

証券種類Ordinary Share

決算期末Feb 22

本社所在地999 West Broadway, Suite 720

都市VANCOUVER

証券取引所NASDAQ Capital Market Consolidated

国Canada

郵便番号V5Z 1K5

電話番号17783310962

ウェブサイトhttps://www.essapharma.com/

企業コードEPIX

上場日Feb 22, 2021

最高経営責任者「CEO」Dr. David Ross Parkinson, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Richard M. Glickman, LL.D.

Non-Executive Independent Chairman of the Board

51.70K

--

Mr. David Sidney Wood, CPA

Chief Financial Officer

33.34K

-0.74%

Mr. Scott Requadt

Independent Director

30.00K

--

Mr. Peter Virsik

Chief Operating Officer, Executive Vice President

7.78K

--

Dr. Alessandra Cesano, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

5.12K

--

Ms. Marella Thorell

Independent Director

2.88K

--

Mr. Franklin M. Berger

Independent Director

--

Mr. Sanford (Sandy) Zweifach, CPA

Independent Director

--

Dr. David Ross Parkinson, M.D.

President, Chief Executive Officer, Director

--

Mr. Alex Martin

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Richard M. Glickman, LL.D.

Non-Executive Independent Chairman of the Board

51.70K

--

Mr. David Sidney Wood, CPA

Chief Financial Officer

33.34K

-0.74%

Mr. Scott Requadt

Independent Director

30.00K

--

Mr. Peter Virsik

Chief Operating Officer, Executive Vice President

7.78K

--

Dr. Alessandra Cesano, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

5.12K

--

Ms. Marella Thorell

Independent Director

2.88K

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Fri, Sep 19

株主統計

種類

株主統計

比率

BVF Partners L.P.

24.66%

Soleus Capital Management, L.P.

9.22%

Tang Capital Management, LLC

9.09%

BML Capital Management LLC

8.92%

Morgan Stanley & Co. LLC

8.82%

他の

39.28%

株主統計

比率

BVF Partners L.P.

24.66%

Soleus Capital Management, L.P.

9.22%

Tang Capital Management, LLC

9.09%

BML Capital Management LLC

8.92%

Morgan Stanley & Co. LLC

8.82%

他の

39.28%

種類

株主統計

比率

Hedge Fund

50.42%

Investment Advisor

11.72%

Research Firm

11.40%

Corporation

3.54%

Individual Investor

2.08%

Venture Capital

0.09%

Investment Advisor/Hedge Fund

0.08%

他の

20.68%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

91

32.28M

72.72%

-18.24M

2025Q1

96

33.48M

75.44%

-17.56M

2024Q4

101

34.20M

77.05%

-15.63M

2024Q3

97

36.44M

82.10%

-7.65M

2024Q2

110

36.54M

82.36%

-10.99M

2024Q1

138

36.33M

81.91%

-11.35M

2023Q4

143

35.77M

81.03%

-12.57M

2023Q3

161

36.59M

82.99%

-18.42M

2023Q2

177

36.37M

82.51%

-21.24M

2023Q1

185

36.21M

82.14%

-19.98M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BVF Partners L.P.

8.75M

19.71%

--

Apr 09, 2025

Soleus Capital Management, L.P.

2.26M

5.1%

--

Apr 23, 2025

Tang Capital Management, LLC

4.30M

9.69%

--

Mar 31, 2025

BML Capital Management LLC

4.22M

9.51%

--

Apr 24, 2025

Morgan Stanley & Co. LLC

4.20M

9.46%

+10.76K

+0.26%

Mar 31, 2025

Opaleye Management Inc.

2.21M

4.98%

--

Mar 31, 2025

Pfizer Inc

1.68M

3.77%

--

Mar 31, 2025

Berger (Franklin Milan)

784.40K

1.77%

--

Jan 08, 2025

BofA Global Research (US)

698.27K

1.57%

-114.04K

-14.04%

Mar 31, 2025

Aldebaran Capital, LLC

569.29K

1.28%

+171.77K

+43.21%

Mar 31, 2025

詳細を見る

0.211USD

ESSA Pharma Inc

0.211

概要

企業名

金融

分析